Nav: Home

How to select anti-hepatitis B virus agents for drug-resistance patients?

September 24, 2008

HBV infection may lead to acute liver disease, chronic active hepatitis, liver cirrhosis, and hepatocellular carcinoma. Over 350 million people worldwide are estimated to be infected chronically by HBV and are therefore at risk of liver failure, cirrhosis, or hepatocellular carcinoma. The principal treatment for chronic hepatitis B (CHB) involves the use of interferon alpha (IFN-a) or nucleoside analogs. In vitro analysis of clinical HBV isolates is currently difficult for lacking of HBV cellular culture model

A research article to be published on 14 June 2008, in the World Journal of Gastroenterology addresses this question. The research team led by Prof. Yin-Ping Lu from Union Hospital of Tongji Medical College reportd a useful strategy to select anti-HBV agents for drug-resistance patients. The full-length HBV genomic DNA from chronic hepatitis B patients were amplified by polymerase chain reaction (PCR). The amplified HBV DNA fragments were inserted into an universal HBV expression vector respectively. The recombinant plasmids containing 1.1 copies of HBV genome were transient transfected into Huh7 cells and antiviral susceptibility of lamivudine and adefovir were analyzed in vitro model system. Furthermore, the antiviral susceptibility of adefovir in vivo were observed subsequently.

Eight clinical HBV isolates form different individual with lamivudine-resistance were cloned into HBV expression vector, and recombinant plasmids were transcient transfected into Huh7 cells. The results indicated that HBV genome of clinical HBV isolates could effectively replicate and be expressed in Huh7 cells. Adefovir but not lamivudine inhibited HBV replication both in vitro and in vivo.

The novel method described in this article enables rapidly selecting of anti-HBV agents in clinic and will be useful in future studies of antiviral therapy for chronic hepatitis B.
-end-
Reference: Lu YP, Guo T, Wang BJ, Dong JH, Zhu JF, Liu Z, Lu MJ, Yang DL. Replication of clinical HBV isolate and its application for selecting antiviral agents for chronic hepatitis B patients. World J Gastroenterol 2008; 14(22):3490-3496
http://www.wjgnet.com/1007-9327/14/3490.asp

Correspondence to: Dr. Yin-Ping Lu, Department of Virology, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan 430022, Hubei Province, China.
yinpinglu@163.com
Telephone: +86-27-85726121 Fax: +86-27-85776343

About World Journal of Gastroenterology

World Journal of Gastroenterology (WJG), a leading international journal in gastroenterology and hepatology, has established a reputation for publishing first class research on esophageal cancer, gastric cancer, liver cancer, viral hepatitis, colorectal cancer, and H pylori infection. It provides a forum for both clinicians and scientists. WJG has been indexed and abstracted in Current Contents/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch) and Journal Citation Reports/Science Edition, Index Medicus, MEDLINE and PubMed, Chemical Abstracts, EMBASE/Excerpta Medica, Abstracts Journals, Nature Clinical Practice Gastroenterology and Hepatology, CAB Abstracts and Global Health. ISI JCR 2003-2000 IF: 3.318, 2.532, 1.445 and 0.993. WJG is a weekly journal published by WJG Press. The publication dates are the 7th, 14th, 21st, and 28th of every month. The WJG is supported by The National Natural Science Foundation of China, No. 30224801 and No. 30424812, and was founded with the title China National Journal of New Gastroenterology on October 1, 1995, and renamed WJG on January 25, 1998.

About The WJG Press

The WJG Press mainly publishes World Journal of Gastroenterology.

World Journal of Gastroenterology

Related Hepatocellular Carcinoma Articles:

Contrast-enhanced ultrasound predicts nodule transformation to hepatocellular carcinoma
An article published ahead-of-print in the January 2020 issue of the American Journal of Roentgenology has identified sonographic biomarkers that can predict eventual malignant transformation of pathologically confirmed cirrhotic nodules for patients at risk for hepatocellular carcinoma (HCC).
Lifetime indoor tanning associated with squamous cell carcinoma cancer
This observational study used data from nearly 160,000 women in Norway to examine lifetime indoor tanning and risk of squamous cell carcinoma, one of the most common types of cancer worldwide.
Aspirin improves liver function after embolization of hepatocellular carcinoma
Aspirin therapy is associated with both improved liver function test results and survival after transarterial embolization for hepatocellular carcinoma, according to an ahead-of-print article by F.
Percutaneous ablation vs. surgery for hepatocellular carcinoma
Compared to surgery, percutaneous liver ablation interventions (IRs) in patients with hepatocellular carcinoma (HCC) are associated with lower inhospital mortality, length of hospital stay (LOS), and hospitalization costs, according to a study to be presented at the ARRS 2019 Annual Meeting, set for May 5-10 in Honolulu, Hawaii.
Immune checkpoint inhibitor combo efficacious for patients with neuroendocrine carcinoma
A combination of the anti-CTLA-4 immunotherapeutic ipilimumab (Yervoy) and the anti-PD-1 immunotherapeutic nivolumab (Opdivo) showed clinical benefit among patients with rare, high-grade neuroendocrine carcinoma, according to results from the DART phase II clinical trial presented at the AACR Annual Meeting 2019, March 29-April 3.
Osteopontin: A new emerging role in HCV-related hepatocellular carcinoma
A research team based in Japan led by Kanazawa University has demonstrated the effect of osteopontin on hepatitis C virus replication and interferon signaling in cancer stem cells.
New combined treatment shows promise in hepatocellular carcinoma
New combined treatment shows promise in Hepatocellular Carcinoma. A combination of mTOR inhibitors and Phenformin leads to an increase in overall survival.
Screening for hepatocellular carcinoma in patients with hepatitis C-related cirrhosis achieving sustained virological response is likely to be cost effective
A Canadian study suggests that biannual or annual ultrasound screening for HCC is likely to be cost effective after a sustained virological response in those with hepatitis C-related cirrhosis, but not in those with advanced fibrosis without cirrhosis.
Alcoholic liver disease replaces hepatitis C infection as the leading cause of liver transplantation in patients without hepatocellular carcinoma in the USA
Two independent US studies confirm that, from 2016 onwards, alcoholic liver disease has led to more liver transplants than hepatitis C infection in patients without hepatocellular carcinoma (HCC).
Hepatocellular carcinoma: Resection vs. transplantation
Liver transplantation is the gold standard for treating early hepatocellular cancers.
More Hepatocellular Carcinoma News and Hepatocellular Carcinoma Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Making Amends
What makes a true apology? What does it mean to make amends for past mistakes? This hour, TED speakers explore how repairing the wrongs of the past is the first step toward healing for the future. Guests include historian and preservationist Brent Leggs, law professor Martha Minow, librarian Dawn Wacek, and playwright V (formerly Eve Ensler).
Now Playing: Science for the People

#566 Is Your Gut Leaking?
This week we're busting the human gut wide open with Dr. Alessio Fasano from the Center for Celiac Research and Treatment at Massachusetts General Hospital. Join host Anika Hazra for our discussion separating fact from fiction on the controversial topic of leaky gut syndrome. We cover everything from what causes a leaky gut to interpreting the results of a gut microbiome test! Related links: Center for Celiac Research and Treatment website and their YouTube channel
Now Playing: Radiolab

The Flag and the Fury
How do you actually make change in the world? For 126 years, Mississippi has had the Confederate battle flag on their state flag, and they were the last state in the nation where that emblem remained "officially" flying.  A few days ago, that flag came down. A few days before that, it coming down would have seemed impossible. We dive into the story behind this de-flagging: a journey involving a clash of histories, designs, families, and even cheerleading. This show is a collaboration with OSM Audio. Kiese Laymon's memoir Heavy is here. And the Hospitality Flag webpage is here.